NCT00274183

Brief Summary

Nonalcoholic fatty liver disease (NAFLD) is an emerging and important disease in Taiwan. However, the prevalence and clinical characteristics have not been studied well. The purpose of this study is to resolve the aforementioned problem.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
614

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2006

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2006

Completed
1 day until next milestone

First Submitted

Initial submission to the registry

January 2, 2006

Completed
8 days until next milestone

First Posted

Study publicly available on registry

January 10, 2006

Completed
12.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2018

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2018

Completed
Last Updated

April 9, 2019

Status Verified

December 1, 2018

Enrollment Period

12.9 years

First QC Date

January 2, 2006

Last Update Submit

April 7, 2019

Conditions

Fatty Liver

Outcome Measures

Primary Outcomes (1)

  • non-alcoholic fatty liver disease

    confirmed by liver ultrasonography

    one year

Eligibility Criteria

Age6 Years - 18 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodProbability Sample
Study Population

Obese children will be enrolled from elementary school and high school in Taiwan

You may qualify if:

  • diagnosis of fatty liver

You may not qualify if:

  • other hepatic diseases

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Far Eastern Memorial Hospital

Taipei, 220, Taiwan

Location

Related Publications (2)

  • Lin YC, Chang PF, Chang MH, Ni YH. Genetic variants in GCKR and PNPLA3 confer susceptibility to nonalcoholic fatty liver disease in obese individuals. Am J Clin Nutr. 2014 Apr;99(4):869-74. doi: 10.3945/ajcn.113.079749. Epub 2014 Jan 29.

    PMID: 24477042DERIVED

  • Lin YC, Chang PF, Chang MH, Ni YH. A common variant in the peroxisome proliferator-activated receptor-gamma coactivator-1alpha gene is associated with nonalcoholic fatty liver disease in obese children. Am J Clin Nutr. 2013 Feb;97(2):326-31. doi: 10.3945/ajcn.112.046417. Epub 2012 Dec 26.

    PMID: 23269818DERIVED

Biospecimen

Retention: SAMPLES WITH DNA

Serum, WBC DNA

MeSH Terms

Conditions

Fatty Liver

Condition Hierarchy (Ancestors)

Liver DiseasesDigestive System Diseases

Study Officials

  • Yu-Cheng Lin, M.D.

    Far Eastern Memorial Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 2, 2006

First Posted

January 10, 2006

Study Start

January 1, 2006

Primary Completion

December 1, 2018

Study Completion

December 31, 2018

Last Updated

April 9, 2019

Record last verified: 2018-12

Locations

TW(1)